Where is Innoviva (INVA) Headed According to Analysts?

Innoviva, Inc. (NASDAQ:INVA) is one of the best affordable biotech stocks to invest in now. On August 11, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Innoviva, Inc. (NASDAQ:INVA) to $45 from $40 while keeping a Buy rating on the shares.

The same day, Oppenheimer initiated coverage of Innoviva, Inc. (NASDAQ:INVA) with an Outperform rating and $35 price target.

The firm told investors that it considers Innoviva, Inc.’s (NASDAQ:INVA) specialty therapeutics and royalty commercial results to be significant factors that can drive share outperformance.

Innoviva, Inc. (NASDAQ:INVA) is involved in the development, commercialization, and financial management of biopharmaceuticals.

While we acknowledge the potential of INVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.